|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Debt securities held to maturity, net of allowance for credit losses of $1 at March 31, 2025 and December 31, 2024 (Fair value of $813,125 at March 31, 2025 and $807,838 at December 31, 2024) | ||||||||||||||||||||
| Debt securities available for sale | ||||||||||||||||||||
| Debt securities held to maturity, net of allowance for credit losses of $1 at June 30, 2026 and December 31, 2025 (Fair value of $790,440 at June 30, 2026 and $812,580 at December 31, 2025) | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses on loans | ||||||||||||||||||||
| Loans, net of allowance for credit losses on loans | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Identifiable intangibles, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Noninterest-bearing deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Bank Term Funding Program borrowings | ||||||||||||||||||||
| Securities sold under repurchase agreements | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Shareholders' Equity: | ||||||||||||||||||||
| Common stock and additional paid-in-capital Common stock (no par value), authorized: 150,000 shares issued and outstanding: 23,002 at June 30, 2026 and 24,623 at December 31, 2025 | ||||||||||||||||||||
| Deferred compensation | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total Shareholders' Equity | ||||||||||||||||||||
| Total Liabilities and Shareholders' Equity | ||||||||||||||||||||
Loading...
